XTL Biopharmaceuticals Ltd. (TLV:XTLB)

Israel flag Israel · Delayed Price · Currency is ILS · Price in ILA
3.900
-0.200 (-4.88%)
Jun 5, 2025, 5:24 PM IDT
-56.18%
Market Cap 35.26M
Revenue (ttm) 1.64M
Net Income (ttm) -3.74M
Shares Out 881.39M
EPS (ttm) -0.01
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 345,971
Average Volume 355,856
Open 4.100
Previous Close 4.100
Day's Range 3.900 - 4.200
52-Week Range 0.063 - 11.200
Beta 1.04
RSI 32.25
Earnings Date May 12, 2025

About XTL Biopharmaceuticals

XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. Its lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren’s syndrome. The company has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1993
Employees 10
Stock Exchange Tel Aviv Stock Exchange
Ticker Symbol XTLB
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

There is no news available yet.